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ABSTRACT 
In this study molecular modelling is introduced as a novel approach for the development of 
pharmaceutical solid dispersions. A computational model based on quantum mechanical 
(QM) calculations was used to predict the miscibility of various drugs in various polymers by 
predicting the binding strength between the drug and dimeric form of the polymer. The 
drug/polymer miscibility was also estimated by using traditional approaches such as Van 
Krevelen/Hoftyzer and Bagley solubility parameters or Flory Huggins interaction parameter 
in comparison to the molecular modelling approach.   
The molecular modelling studies predicted successfully the drug9polymer binding energies 
and the preferable site of interaction between the functional groups. The drug9polymer 
miscibility and the physical state of bulk materials, physical mixtures and solid dispersions 
were determined by thermal analysis (DSC/MTDSC) and X9ray diffraction. The produced 
solid dispersions were analysed by X9ray photoelectron spectroscopy (XPS), which 
confirmed not only the exact type of the intermolecular interactions between the drug9
polymer functional groups but also the binding strength by estimating the N9coefficient 
values.   The findings demonstrate that QM9based molecular modelling is a powerful tool to 
predict the strength and type of intermolecular interactions in a range of drug/polymeric 
systems for the development of solid dispersions. 
Keywords: solid dispersions, quantum mechanics, molecular modelling, miscibility, drug9
polymer interactions. 
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INTRODUCTION  
Drug9polymer miscibility is a significant factor to consider when designing solid dispersions 
for pharmaceutical dosage forms 1. The interactions between small molecule drugs and 
polymers in a polymeric matrix system determines the nature of the drug loading inside the 
polymer matrix, such as oversaturated or under saturated, thus play a vital role in determining 
the long9term stability of the formulated product. Therefore, the characterisation and 
prediction of drug–polymer miscibility and more importantly drug solubility at various 
conditions has become an emerging topic in pharmaceutical research for the development of 
solid dispersions 1–3. The dispersion of a small drug molecule being miscible into a polymer 
matrix is mechanistically a complex process. Both the repulsive and attractive intra9 and 
intermolecular forces (e.g. dispersion force, dipole–dipole interaction, and hydrogen bonding 
forces) present in the system may further complicate the process. As a mechanistic rule, the 
molecular level mixing requires a step of balancing and/or breaking the crystalline lattice of 
drug molecules (with high activation energy) in the first instance. Subsequently, the polymer 
swelling (a process of polymer chain segment absorbing drug molecule) and rebuilding of the 
possible interactions inside the mixture occur 4. The drug molecule (either crystalline or 
amorphous) may have significantly different physical properties within the polymer matrices 
after processing due to the different energy input and possible inter9molecular interactions 
that are required to form a solid dispersion. In terms of the random distribution of small drug 
molecules into the polymeric matrices, the miscible drug content demonstrates amorphous 
characteristics. 
The lattice9based Flory–Huggins (F–H) theory (Flory 1952) is well known for the 
prediction of polymer–solvent or polymer–polymer interactions based on the Gibbs free 
energy change before and after mixing 5. The F9H theory can be successfully applied to 
determine the interaction parameter therefore signifying the strength of the interactions 
between two compounds during their melting. Recent publications applying the F–H theory 
in solid dispersions focus on obtaining the F–H interaction parameter, χ, by the melting point 
depression method 6, 7. The employment of F–H theory for the prediction of the 
intermolecular interactions in pharmaceutical binary systems can provide important insights 
in the development of solid dispersions processed by hot melt extrusion (HME) for example. 
However, the theory assumes random distribution of the segments, which may not be suitable 
in cases where there are strong polar forces or specific interactions, such as hydrogen 
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bonding, between the components of the blends 8.  A deeper understanding of the relatively 
stronger interactions between the drug and the polymer has to be built on insights of the 
atomic level interactions. Molecular modelling approach is a powerful addition to the F9H 
theory to characterise the drug9polymer interactions through both visualisation of the 
interaction and estimation of the strength of the interactions.  To date, a number of molecular 
mechanics (MM)9based molecular dynamics (MD) simulation studies 9912 have been 
performed to study various molecules (e.g. dissolution of the molecules from the crystal 
surface)13 or to identify drug9polymer miscibility in solid dispersions 14918. Recently, we 19 
reported the use of quantum mechanical (QM) calculations with commercially available 
software (Gaussian 09) to characterise possible drug/polymer interactions. Our calculations 
indicated the existence of hydrogen bonding between the amine group of the drug molecule 
and the carboxyl groups of the polymer among different drug/polymer formulations, which 
was subsequently, confirmed by NMR and X9ray photoelectron spectroscopy (XPS) studies.  
In recent years, hot9melt extrusion (HME) has undergone a renaissance in the research 
and development of pharmaceutical formulations 20. HME is a manufacture processing 
technology that combines the advantages of a solvent9free solid dispersion and has been used 
for a wide range of solid dispersion with increased drug solubility, taste masking of bitter 
APIs, and sustained/controlled release properties 20, 21.  
In this study, we developed a new approach to determine the drug9polymer miscibility 
based on quantum mechanical (QM) calculations, whereby the calculated binding energy 
between the drug and the polymer provides a strong indication for the formation of stable 
solid dispersions. The QM approach was compared with the Hansen solubility parameters 
and F9H estimated values in order to demonstrate the superiority of the molecular modelling 
approach, which not only provides more accurate description of the drug9polymer interaction 
energy, but also predicts the interacting functional groups between both substances. The latter 
was confirmed by X9ray photoelectron spectroscopy (XPS) 22, 23 studies on the produced 
HME solid dispersions. XPS has been reported as a valuable tool for the characterisation of 
solid dispersions by providing information on the nature (e.g. H9bonding) and specific site of 
chemical bonding on the surface of the solid dispersion.  
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MATERIALS AND METHODS 
Materials. Propranolol HCl (PRP) and Diphenhydramine HCl (DPD), Paracetamol (PMOL), 
Ibuprofen (IBU), Dichlofenac Na (Df9Na) and Hydrocortisone (HCS) were purchased from 
Sigma Aldrich (London, UK) of ≥ 98% purity. Eudragit L100 (L100), Eudragit EPO (EPO) 
and Eudragit L100955 were kindly donated by Evonik Pharma Polymers (Darmstadt, 
Germany). Kollidon VA64 (VA64) was kindly donated by BASF (Germany). All materials 
were used as received. 
Hot(melt extrusion (HME) processing. Drug/polymer blends (PRP/L100, PRP/L100955, 
DPD/L100, DPD/L100955, PMOL/VA64, IBU/VA64 and IBU/EPO) were blended in 100 g 
batches for 10 min each with a Turbula (TF2, Basel) mixer. The extrusion of all batches was 
performed using a Randcastle single9screw extruder (RCP0625) equipped with a 59mm rod 
die at 100°C/140°C/155°C/155°C/150°C (Feeder → Die) temperature profiles for PRP and 
DPD based formulations, 100°C/113°C/115°C/115°C/115°C (Feeder → Die) for PMOL and 
70°C/85°C/85°C/85°C/80°C (Feeder → Die) for IBU based formulations. The screw speed 
was set at 15rpm for all drug/polymer binary compositions. The produced extrudates 
(strands) were grinded by using a Ball Mill system (Retsch, Germany) to obtain granules 
(<500 µm) at a rotational speed of 400 rpm for 5 min. The drug9polymers composition 
consisted of PRP/L100, PRP/L100955, DPD/L100 and DPD/L100955 were extruded at ratios 
of 10/90 w/w. These four extruded formulations (comprising oppositely charged drugs and 
polymers) were used in XPS analysis to determine possible intermolecular interactions.  
Hansen solubility parameters: Predictions of drug/polymers miscibility. The theoretical 
drug9polymers miscibility was determined by applying the Hansen solubility parameters (δ) 
for both drugs as well as the polymers. The Hoftyzer and van Krevelen method was used to 
calculate all drug polymers solubility parameters by considering the chemical structural 
orientations 24 according to the following equation: 
δ2= δ2d+δ
2
p+δ
2
h  (1) 
Here, 
 = Σ  , 	 =

Σ
 	 ,  = 
Σ  
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i = structural groups within the molecule, δ =   the total solubility parameter. Fdi = molar 
attraction constant due to molar dispersion forces, F2pi = molar attraction constant due to 
molar polarization forces, Ehi = hydrogen bonding energy, and Vi = group contribution to 
molar volume 
By using the two – dimensional approach Bagley et al. 25 introduced the volume – dependent 
solubility parameter which is defined as δv, where δp and δd were used to predict the 
combined thermodynamic effects on the drug9polymers miscibility over hydrogen bonding 
energy, h. 
 = 
 + 	 	(2) 
Flory Huggins (F(H) theory for the prediction of drug/polymers interaction parameter. 
The F–H interaction parameter, χ, was correlated with temperature dependence, as in many 
simplified cases. The interaction parameter of the model system was determined at two 
different conditions using the Nishi–Wang Eq. 3 26 equation based on melting point 
depression data and Hildebrand and Scott Eq. 4 27 correlations with solubility parameter, 
respectively. The F9H interaction parameter (χ) of the drug/polymers as shown in Table 2 
binary mixtures were calculated by using the following equations. The value determined by 
Eq. 3 represents the interactions between the two substances, specifically at the melting 
temperature, which may not be extrapolated to other temperatures. 
 
Where, υ is the molar volume of the repeating unit, m is the degree of polymerization,  φ is 
the volume fraction and χ is the crystalline– amorphous polymer interaction parameter, Tm is 
the crystalline melting peak of the pure drugs and Tom is the melting endotherm of the drug9
polymer physical blends. 
F9H interaction parameter (χ) can be also estimated by the method developed by Hildebrand 
and Scott according to the following Eq. 4 27. 
 
 
)3(])1()1()
1
1([ln
11 2
0 drugpolydrugdrug
poly
drug
polydrug
drug
mm
mH
R
TT
φχφφ
υ
υ
−+−×−+

−=− −
)4(
)( 2
RT
polydrug δδυ
χ
−
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Where, R is the gas constant, T is the absolute temperature, and v the volume per lattice site 
and δdrug and δpoly are solubility parameters of drugs and polymers respectively. 
Thermal analysis (DSC and MTDSC). A Mettler9Toledo 823e (Greifensee, Switzerland) 
differential scanning calorimeter (DSC) was used to carry out thermal analysis of the bulk 
APIs, polymers, drug/polymer binary physical mixtures and extruded formulations (n=3). 
About 395 mg of each samples were placed in sealed aluminium pans with pierced lids.  The 
samples were heated, cooled and reheated at 10°C/min from 0°C to 220°C under an 
atmosphere of dry nitrogen. In addition modulated temperature differential scanning 
calorimetry (MTDSC) studies were performed from 20oC to 150oC with an underlying 
heating rate of 1
o
C/min. The pulse height was adjusted to 192oC with a temperature pulse 
width of 15930 s.  
Molecular Modelling. The dimeric structures of L100, L100955, EPO and VA64 and the 
monomeric structures of PRP, DPD, PMOL, IBU, Df9Na and HCS were constructed by 
program Gaussview 28. Hydrogen bonding patterns were identified by placing the drug 
molecule within the proximity of the dimeric structure of the polymer and then 
energy optimised to local minima at the  M0692x/6931G** level and verified by frequency 
calculations using Gaussian09. A counterpoise procedure 29 was employed to correct for the 
effect of basis set superposition error (BSSE) for the binding energy between the drug 
molecule and the dimer.  
X(ray photoelectron spectroscopy (XPS) analysis. X9ray photoelectron spectra (XPS) were 
measured on a Kratos Axis Ultra9DLD using a monochromatic Al Kα X9ray source (120 W) 
and an analyser pass energy of 160 eV (survey scans) or 20 eV (high resolution scans); the 
pressure during analysis was 1×1099 Torr.  All data were referenced to the C(1s) signal at 
285.0 eV attributable to unsaturated C9C/C9H bonds 22.  Quantification and curve fitting was 
performed in CasaXPSTM (Version 2.3.15) using elemental sensitivity factors supplied by the 
manufacturer. All samples were run in triplicate. 
 
RESULTS AND DISCUSSIONS 
Predictions of drug/polymers miscibility: Hansen solubility parameters. Up to date there 
are several approaches employed to estimate the drug/polymer miscibility based in the 
determination of the solubility parameter. The theoretical approaches derived from the 
solubility parameter calculations suggest that compounds (e.g. drug or polymer) with similar 
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δ values are likely to be miscible. This is because the energy of mixing which is released 
from intra9molecular interactions is balanced with the energy of mixing from intermolecular 
interactions 30. It has been reported that compounds with Xδ < 7 MPa1/2 are likely to be 
miscible and compounds with Xδ > 10 MPa1/2 are likely to be less miscible or immiscible 30. 
It can be seen in Table 1 that the difference between the calculated solubility 
parameters indicate that all of the drugs used are likely to be miscible with all polymers (Xδ 
< 7 MPa1/2). By using the Van Krevelen/Hoftyzer method, the calculated Xδ values for 
DPD/L100, DPD/ L100955, PRP/L100 and PRP/L100955 are 5.0, 3.9, 0.81 and 0.29 MPa1/2, 
respectively indicating complete drug/polymer miscibility. Similarly, Xδ values estimated for 
HCS/L100 and Df9Na/L100 are 2.59 and 3.32 MPa1/2, respectively suggesting that both HCS 
and Df9Na are likely to be miscible with L100. On the other hand PMOL is unlikely to be 
miscible with EPO as the calculated Xδ falls in the range close to 7MPa1/2 threshold while 
IBU seems highly miscible with EPO (Xδ is 3.59 MPa1/2). However, both PMOL and IBU are 
miscible with VA64. 
 Furthermore, to determine the solubility parameters more precisely a two9dimensional 
approach introduced by Bagley et al. 25 can be also used to predict drug–polymer miscibility 
(Table 1). Previous studies showed that, even though Van9Krevelen method has widely been 
used to screen drug/polymer miscibility, the estimated solubility parameters were not always 
accurate. For example, Maniruzzaman et al. 20 reported a study where the difference of the 
calculated partial solubility parameters of the model drug PMOL and the VA64 polymer was 
less than 7 MPa1/2. However, PMOL/VA64 were found immiscible and the solid9state 
characterisation (e.g. DSC, XRPD) showed that PMOL existed as separate amorphous9
amorphous phase from the polymer after extrusion. In the same study the Bagley approach 
provided a more accurate estimation of the drug9polymer miscibility complementing the 
findings from the solid9state analysis. 
Therefore, the two – dimensional approach is used to determine the drug – polymer 
miscibility by calculating the distance (Ra(v)) using the Pythagorean Theorem 
20. By this 
approach two components are considered miscible when Ra(v) ≤5.6MPa
1/2.   Table 1 shows 
that the δh values of the polymers are substantially different compared to the δp and δd. 
However the distances calculated for DPD/L100, DPD/L100955, PRP/L100 and PRP/L1009
55 blends indicate that both DPD and PRP are miscible with L100 and L100955 polymers. 
Similarly, Ra(v) values calculated for Df9Na/L100 (6.97 MPa
1/2) and HCS/L100 (2.95 MPa1/2) 
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indicated that higher values for hydrogen bonding have favoured HCS to be miscible with 
L100 while Df9Na to be immiscible. The estimation of the Van Krevelen/Hoftyzer partial 
solubility parameter indicates that Df9Na is miscible with L100 but the Bagley parameter 
completely opposes this prediction.  However, both the Van Krevelen/Hoftyzer and Bagley 
solubility parameters indicate that PMOL is not miscible with EPO. 
The Hansen solubility parameter is considered a reliable approach to predict possible 
drug polymer miscibility, but the limited available data for different group contributions 
render this approach questionable. It does not also take in account the effect of chain 
conformation, including branching and linkages between monomer units and the molecular 
weight (MW) of compounds. These are considered important factors for the solubility of the 
drug molecule into polymer matrixes and thus in many cases the calculated solubility 
parameters provide misleading estimations of the drug/polymer miscibility. 
Flory Huggins (F(H) theory for the prediction of drug/polymers interaction parameter. 
The Flory–Huggins (F–H) theory is another approach that describes the polymer–drug or 
polymer–polymer miscibility on the basis of Gibbs free energy change before and after 
mixing. It assumes that each molecule occupies one site in the lattice and assumes random 
distribution of the segments 31. The presence of strong bonds or intermolecular forces (e.g. H9
bonding) in solid dispersions often limits the mobility of the chains, which are forced into 
non9random configurations 6, 31. Therefore, the presence of such strong interactions in the 
systems makes the suitability of F9H theory unsatisfactory as it underestimates those 
interactions.  
In order to determine the F9H interaction parameter between the investigated drugs–
polymers blends, the heat of fusion and melting peaks of bulk drug substances, polymers and 
physical blends were determined by thermal analysis. In the DSC thermograms the bulk PRP, 
DPD, HCS, Df9Na, PMOL and IBU showed sharp melting peaks at 166.65oC, 170.83oC, 
226.12oC, 289.60oC, 170.00oC and 79.50oC, respectively with heat of fusion / enthalpy (XH) 
values of 126.25 J/g, 124.59 J/g, 114.92 J/g, 161.06 J/g, 137.06 J/g and 151.17 J/g, 
respectively. The molecular volumes of all drugs and polymers were estimated from the 
functional group contribution and by using Eqs. 3 & 4 the average value of χ is calculated as 
shown in Table 2.   
The negative values of the interaction parameter in Table 2 indicate that there is a net 
attraction force (such as dispersion, polar or hydrogen bonding) between the components in a 
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binary mixture. Therefore higher absolute values of χ, suggest stronger interactions between 
drug/polymers blends. In Table 2, it can be seen that L100 facilitates stronger interactions 
with different drugs compared to those of L100955. Similarly, PMOL showed a stronger 
interaction with VA64 compared to that of EPO, which is in agreement with the solubility 
parameter calculations.  As expected, IBU also showed relatively strong interactions with 
both EPO and VA64.  
As mentioned in a previous paragraph, the F9H parameter cannot provide successful 
estimations when multiple stronger interactions (such as H9bonding) appear in the 
drug/polymer systems 6. Another key limitation is that a range of experimental data is 
required in order to apply F9H equation, which makes the approach questionable if the data 
are not accurate 8. Furthermore, the F9H interaction parameter cannot reveal the mechanism 
or site of interaction in the drug9polymer dispersions. Therefore, a new novel method that 
could provide both the atomistic and quantitative descriptions of drug9polymer interactions is 
of immense need for the development of solid dispersions for various drug9polymer systems.  
Thermal analysis. DSC was used to analyze the glass transition temperature (Tg) of all pure 
drugs, polymers, drug/polymer binary mixtures and extrudates (Table 3, Supp. Fig. 197). 
Thermal analysis has been used as a valuable tool to predict drug9polymer miscibility 19, 32934. 
According to the Gordon–Taylor equation, if a drug and polymer are miscible the mixture 
will show a single Tg that ranges between the Tg of pure components 20. Thus, the theoretical 
prediction of Hansen solubility parameters by using Van Krevelen method and F9H 
interaction parameters was complemented by DSC studies to access drug /polymer 
miscibility.  
The DSC results of bulk drug substances, bulk polymers, physical mixtures and melt 
extrudates are presented in Table. 3. All physical mixtures exhibited melting peaks of the 
drug at slightly decreasing melting temperatures due to possible drug/polymer interactions 
and partial miscibility. In contrast, no drug melting transitions were observed PRP/L100, 
PRP/L100955, DPD/L100 and DPD/L100 solid dispersions prepared by HME processing. 
The solid dispersions exhibited only a single Tg at temperatures between the Tg of the drug 
and the polymer, which is strong evidence that PRP and DPD are miscible with both L100 
and L100955 polymers. Similar results were also obtained for the other drug/polymer blends 
with an exception for the PMOL/VA64 extrudates where a phase separation was observed 
(PMOL and VA64 were present in two distinct amorphous phases). 
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Molecular Modelling. Molecular modelling has been used extensively to assist in 
understanding experimental data and to predict the atomic and molecular properties that can 
provide guidance for experiment design. In the current study, the computation of binding 
strength between the drug and dimeric form of the polymer was carried out with a QM9based 
molecular modelling approach using commercial software package Gaussian09. In the QM9
based calculations, the total energy of the system is calculated with respect to all atomic 
coordinates and thus the sum of electronic energy and repulsion energy between the nuclei 
and electrons. Because all electrons within the system are explicitly considered, the QM 
approach is capable of characterising with accuracy non9bonded interactions, such as 
hydrogen bonds and charge9charge interactions. Nonetheless, the present approach focuses on 
the intrinsic strength of H bonds and charge9charge interactions between the drug molecule 
and a small fragment of the polymer, which represents predominantly the polar forces present 
within the complex of drug9polymer carrier (Fig. 192).  It does not take consideration of the 
effect of the full polymeric matrix to drug loading and the process of polymer chain swelling 
to absorb the drug molecules, both of which can also play a part in determining drug9polymer 
miscibility. Thus, the binding energy obtained from our QM calculations should be an 
underestimate compared to the free energy estimated using the F9H theory.    
A range of polymers (in their dimeric form) and model drugs were selected to study 
the strength of hydrogen bonding interactions and to probe the feasibility of identifying 
possible drug – polymer interactions prior the manufacturing of solid dispersions. The drug9
polymer interaction patterns were identified by placing the drug molecule within the 
proximity of the dimer and then energy optimised to a local energy minimum. Based on these 
optimised configurations of drug9dimer interactions, the binding energy was calculated using 
the following equation: 
Ebinding= 9[Ecomplex9(Edrug+Edimer)]   (5) 
The term Ebinding is the electronic energy component and also the dominant component of the 
enthalpy term (XH) for the formation of the drug9dimer complexes. In all of the 
drug/polymers combinations primarily two different H bonding were detected with the donor9
acceptor distance at ~2 Å. All possible H bonding were shown in dash line in Table 4.  
Because the dimers and the drugs interact predominantly through hydrogen bonds, we 
interpret the calculated binding energy as a reflection of the strength of hydrogen bonds. 
Overall, the strength of the interactions is dependent on both the type of the donor and 
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acceptor and the number of hydrogen bonds formed between the drug and the polymer 
(Figure 3 and Table 4). Comparisons between L1009DPD(a) and L1009DPD(b) and between 
L1009559DPD(a) and L1009559DPD(b) (superscripts (a) and (b) denote two possible drug9
dimer binding orientations) show that, with structurally similar polymers L100 and L100955, 
the interactions formed between the tertiary amine and the carboxylate  group via a proton 
(21.1 kcal/mol and 20.0 kcal/mol) are significantly higher than those between the alkoxy (9O) 
group and the protonated carboxylate group (12.8 kcal/mol and 15.0 kcal/mol). In addition, 
other than the interactions involved in tertiary amines, the binding energy arising from one 
hydrogen bond ranges from 12.8 to 15.1 kcal/mol, while the binding energy from two 
hydrogen bonds ranges from 16.1 to 25.3 kcal/mol. On average, the binding strength of two 
H9bond interactions can be stronger by ~5 kcal/mol compared to interactions held through 
one H9bond (Figure 3). Higher binding energy represents more stable drug/polymer 
intermolecular interactions formed after the extrusion process35. Strong H9bonding 
interactions predicted by molecular dynamics suggest drug9polymer miscibility as observed 
by the DSC analysis. 
We have also calculated the binding energy between two other polymers, VA64 and 
EPO with the model drugs PMOL and IBU (Table 4). The results are consistent with those 
from L100 and L100955. The binding energy is predicted at 7.0 kcal/mol without hydrogen 
bond interactions between VA64 and IBU, while it increases to 16.7 kcal/mol when one H 
bond is formed between VA64 and IBU, and to 23.3 kcal/mol when two H bonds are formed 
between VA64 and PMOL. It is also noteworthy that again the tertiary amine from EPO and 
the carboxylate of IBU interacting via a proton forms the strongest interaction (27.9 
kcal/mol). This could be attributed to the fact that the most characteristic chemical property 
of amines is their acid neutralizing capacity (act as bases), thus, giving rise to strong binding 
energy between the amine interacting with the carboxylic acid via a proton 35. This is also 
reflected by comparing between EPO9IBU and VA649IBU, where EPO9IBU(a) and VA649
IBU(b), both held together through one H9bond between the carbonyl (C=O) group and the 
protonated carboxylate group, exhibit similar binding energy (16.3 kcal/mol and 16.7 
kcal/mol). When the donor and acceptor type is altered to tertiary amine and the carboxylic 
acid in EPO9IBU(b), the binding energy increases to 27.9 kcal/mol. In summary, based on the 
drug9dimer combinations listed in Table 4, our results indicate that the strength of the 
interactions is dependent on both the type of the donor and acceptor and the number of 
hydrogen bonds formed between the drug and the polymer. In general, addition of a hydrogen 
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bond between the polymer and the drug may be accompanied by a ~5 to 8 kcal/mol increase 
in binding energy. 
X(ray Photoelectron Spectroscopy (XPS) analysis. XPS analysis was employed to confirm 
the QM predictions by analysing the extruded solid dispersions of two drug9polymer 
formulations (PRP/L100, PRP/L100955, DPD/L100 and DPD/L100955). The surface 
elemental ratios of PRP, DPD, polymers and the extruded formulations were determined 
experimentally by XPS 36938 based on various surveys as depicted in Fig.495. This was 
implemented as a comparison with the anticipated theoretical values derived from the 
structural formula 22. According to the surveys the PRP/L100, PRP/L100 55, DPD/L100 and 
DPD/L100955 showed the amount of N atoms as 0.63%, 0.23%, 0.53% and 0.21%, 
respectively simply indicating lower amount of N atom present in the final extruded 
formulations. 
The N (1s) binding energy (BE) of ~402.035 eV (Fig. 6) in PRP and of ~402.6 eV 
(Fig. 7) in DPD suggests the protonation of the NH+ group  while the slightly higher values of 
N (1s) energy (~402.8 eV) in PRP/L100 extrudates represents further protonation effect of N 
atom as NH4
+.  This observed N 1s peak at BE= ~402.80 eV is in good agreement with the 
previously observed protonation of amine group by Beamson and Briggs 22. The BE peak at 
~402.80 eV (higher than typically observed for amines BE= ~399 eV 9 400.5 eV and much 
more for –NH2
+ group) for N1s is an indication of C9O9NH2
+ structure whereas the O atom 
peak at ~534.40 eV shows the same 39, 40. These results strongly indicate H9bonding 
interactions between the amine group of the API and ester/carboxyl group of the polymer 
(L100) (Fig. 6).   
 Similarly, N 1s peaks from PRP/L100955 and DPD/L100955 also complement the 
observations from PRP/L100 and DPD/L100 formulations. The N (1s) energy of ~402.9 eV 
in DPD/L100 formulation suggests protonation of the amine group as observed for 
aforementioned PRP/L100 formulation. The BE peak at ~402.90 eV (Fig. 7) for N1s is an 
indication of C9O9NH2
+ structure with longer peak shift than that of PRP/L100. As before, we 
concluded that a strong interaction between the amine group of API and ester/carboxyl group 
of polymer through H9interactions has taken place 40942.    
 Furthermore, the calculation of the N9coefficient for all extruded formulations 
indicated the strength of the intermolecular interactions within the solid dispersions. The 
calculated N coefficients for all extruded formulations are summarized in Table 5. The values 
Page 13 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14 
 
in Table 5 clearly show that the N coefficient values of the active L100 extrudates are smaller 
than those of L100955 extrudates. It is accepted that the lower the N9coefficient, the higher 
the amount of protonated N atoms in cationic drugs and thus the stronger the interaction 
between polymer and APIs. 
CONCLUSIONS  
In this study, we exploited the use of quantum mechanical (QM) calculations to predict drug9
polymer interactions by using the drug molecule and the dimeric form of the polymer. In 
general, addition of a hydrogen bond between the polymer and the drug is accompanied by 
~5 to 8 kcal/mol increase in binding energy. The strongest interactions however are between 
the tertiary amines and the carboxylate groups via a proton, with their binding energy ranging 
from 20.0 kcal/mol to 27.9 kcal/mol. The findings from XPS analysis confirmed the site of 
interaction and the strength of H9bonding between the carboxyl group of anionic 
methacrylate co9polymers and the amine group of the active substances. The prediction of 
strong interactions for some of the drug9polymer blends, from the QM calculations, were in 
agreement with the DSC experimental findings, which proved the presence of the molecular 
solid dispersions of the same blends. The QM9based calculations enable the study of drug9
polymer interactions with great detail at the atomistic level and are particularly suited for 
characterising drug9polymer interactions that contain strong hydrogen bonds or charge9
charge interactions. Thus QM9based molecular modelling can broadly be applied for the 
development of pharmaceutical solid dispersions where traditional methods such as Van 
Krevelen solubility parameter or F9H parameter present a limited capacity. 
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Table 1: Estimated solubility parameters of different drugs and polymers using Van Krevelen /Hoftyzer and Bagley methods. 
 
Comp. 
δp 
(MPa
1/2
) 
δd 
(MPa
1/2
) 
δh 
(MPa
1/2
) 
δv 
(MPa
1/2
) 
δ 
(MPa
1/2
) 
Van Krevelen (∆δ)  Bagley (Ra(v) 
∆δ L100 
 (MPa
1/2
) 
∆δ L100(
55 
(MPa1/2) 
∆δ EPO 
(MPa
1/2
) 
∆δ VA64 
(MPa
1/2
) 
Ra(v) 
L100 
Ra(v) 
L100-55 
Ra(v) 
EPO 
Ra(v) 
VA64 
PRP 3.67 19.30 9.90 19.64 21.94 0.81 0.29 - - 3.26 4.67 - - 
DPD 4.05 16.39 5.44 16.89 17.75 5.0 3.9 - - 3.59 4.22 - - 
Df9Na 3.32 24.65 7.82 24.87 26.07 3.32 9 - - 6.97 - - - 
HCS 8.02 19.04 14.65 20.67 25.34 2.59 9 - - 2.95 - - - 
PMOL 7.93 19.67 13.96 21.20 25.39 9 9 6.49  5.79 - - 13.16 12.17 
IBU 5.76 18.47 10.04 19.35 21.80 9 9 2.90 2.20 - - 4.21 5.87 
L100 0.41 19.31 12.03 19.31 22.75 9 9 - - 9 9 9 9 
L100955 0.25 18.22 11.69 18.22 21.65 9 9 - - 9 9 9 9 
EPO 0.65 17.89 6.08 17.90 18.90 9 9 - - 9 9 9 9 
VA64 18.0 0.64 18.01 7.73 19.60 9 9 - - 9 9 9 9 
() = ( −	) + ( − )   
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Table 2: Calculation of F–H interaction parameter of different Drug–Polymer extruded 
formulations. 
Formulations Volume Fractions 
(ø) 
Nishi(Wang 
((χ) 
Hildebrand ( Scott 
((χ x 1094 ) 
PRP/L100 0.1:0.9   0.22 2.89  
PRP/L100955 0.1:0.9 0.08 0.37 
DPD/L100 0.1:0.9 0.20 1.10  
DPD/L100955 0.1:0.9 0.07 0.67  
HCS/L100 0.1:0.9 0.21 1.08 
Df9Na/L100 0.3:0.7 0.01 0.15 
PMOL/VA64 0.5:0.5 2.12 1.60 
PMOL/EPO 0.5:0.5 0.38 0.20 
IBU/EPO 0.4:0.6 0.81 0.35 
IBU/VA64 0.4:0.6 0.61 0.20 
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Table 3: Thermal transitions of pure drugs, polymers and binary mixtures. 
 
Glass transition 
(
o
C) 
Melting endotherm/ 
Enthalpy 
(
o
C /@H, Jg
(1
) 
PRP 36.22 166.65/126.25 
DPD 14.13 170.82/124.59 
Df9Na 9 289.61/161.06 
HCS 82.45 226.12/114.92 
PMOL 24.55 168.84/33.40 
IBU 9 77.9/121.30 
L100 164.38 9 
L100955 83.97 9 
EPO 48.38 9 
VA64 105.0 9 
Physical mixtures (PM) and extruded formulations (EXT) 
 PM 
(
o
C ) 
EXT 
(
o
C ) 
PM 
(
o
C ) 
PRP/L100 98.82 74.84 162.41 
PRP/L100955 71.16 63.36 153.62 
DPD/L100 114.46 76.56 139.19 
DPD/L100955 74.15 62.11 153.62 
PMOL/VA64* 102.22 27.57, 93.47 131.32 
PMOL/EPO 79.38 56.76 159.96 
IBU/VA64 54.83 29.49 76.6 
IBU/EPO 57.40 15.57 76.35 
* Two Tgs were observed for the extruded blend due to phase separation.    
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Table 4: The calculated drug9dimer binding energy using Gaussian09 (energy in kcal/mol). 
The top table is for the dimeric forms of polymer L100 and L100955 and model drugs PRP 
and DPD, while the bottom table is for the dimeric forms of polymer VA64 and EPO and 
model drugs PMOL and IBU. Superscripts (a) and (b) denote two possible drug9dimer 
binding orientations, which were determined by positioning the drug molecule in two 
different orientations (based on its H9bond donor/acceptor groups) relative to the position of 
the dimer prior to the QM optimisation.  
Drug9Poly 
Comb. 
Conformation Energy  
 
Drug9Poly. 
Comb. 
Conformation Energy  
 
L1009
PRP(a) 
  
 
14.5 L1009559
PRP(a)  
  
 
17.8 
L1009
PRP(b)  
  
 
16.1 L1009559
PRP(b) 
 
16.9 
L1009
DPD(a) 
 
 
12.8 L1009559
DPD(a) 
 
15.0 
L1009
DPD(b) 
 
21.1 L1009559
DPD(b) 
 
 
20.0 
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L1009Df9
Na(a) 
 
19.4 L1009HCS(a) 
 
25.3 
L1009Df9
Na(b) 
 
15.1 L1009HCS (b) 15.1 
 
Drug9Poly 
Comb. 
Conformation Energy  
 
Drug9Poly. 
Comb. 
Conformation Energy  
 
VA649IBU 
(a)
 
 
7.0  EPO9IBU(a) 
 
16.3  
VA649IBU 
(b) 
 
16.7  EPO9IBU (b) 
 
27.9  
 
VA649
PMOL 
 
23.3  
 
Table 5: N coefficients of the extruded formulations 
Formulations N 1s Binding Energy Calculated N Coefficient 
1
st
 Fitting (eV) 2
nd
 Fitting (eV) 
PRP/L100 63 100 0.63 
PRP/L100955 58.51 49.49 1.18 
DPD/L100 45.97 54.03 0.85 
DPD/L100955 51.19 48.81 1.05 
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Figures caption list 
Fig. 1 Molecular modelling of PRP and L100 or L100955 pairs (Gaussian09). 
Fig. 2 Molecular modelling of DPD with different polymers (energy optimised to local 
minima at the M0692x/6931G** level and verified by frequency calculations 
using Gaussian09). 
Fig. 3 Binding energy as arranged based on the number of hydrogen bonds (red and 
blue columns for one H bond while green for two H bonds) between the dimeric 
structure of the polymer and the model drugs. Red columns represent the 
binding energy involved in tertiary amines.  
 
Fig. 4 XPS surveys of pure PRP, DPD, L100 and L100955 showing BE peaks of C 1s, 
O 1s, N 1s and Cl 2p atoms and their area ratios. 
Fig. 5 XPS surveys of DPD and PRP based extruded formulations with L100 and 
L100955 polymers (C 1s, O 1s, N 1s and Cl 2p atoms and their area ratios). 
Fig. 6 Molecular structure of PRP and N 1s BE peaks of PRP and extruded 
formulations (from the peak fitting using CasaXPSTM 9 Version 2.3.15). 
Fig. 7 DPD molecular structure and its N 1s BE peaks with DPD/L100 and DPD/L1009
55 extruded formulations (peak fitting performed using CasaXPSTM 9 Version 
2.3.15). 
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Graphical Abstract 
 
Page 24 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



	
					
		
			

			 !"	
#		#	$	%			!&'()		
*&+*&

	'	+	'	,(		


Page 25 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



	



	

	

	
	

 !"!"#$%


Page 26 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



	
		 !" #$%&
%		%'
$(()*+&&,-.)-./0


Page 27 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



	
			
	 !"#"$
!%		&'
%(()* )+)+,&


Page 28 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



	
					
		
					
					
	

 	!	"
	#$%$&'$		
##&%(	()		()	*+'		


Page 29 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



	
		


		

 
!	!"

#$%&'()*)+)
(, -.-./+


Page 30 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
